Nu Med Plus Stock Performance
| NUMD Stock | USD 0.01 0.01 29.00% |
The company owns a Beta (Systematic Risk) of 0.37, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Nu Med's returns are expected to increase less than the market. However, during the bear market, the loss of holding Nu Med is expected to be smaller as well. At this point, Nu Med Plus has a negative expected return of -0.84%. Please make sure to verify Nu Med's variance and the relationship between the value at risk and relative strength index , to decide if Nu Med Plus performance from the past will be repeated at future time.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Nu Med Plus has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's primary indicators remain rather sound which may send shares a bit higher in March 2026. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders. ...more
| Begin Period Cash Flow | 188.5 K | |
| Free Cash Flow | -206.8 K |
NUMD |
Nu Med Relative Risk vs. Return Landscape
If you would invest 3.00 in Nu Med Plus on November 5, 2025 and sell it today you would lose (1.58) from holding Nu Med Plus or give up 52.67% of portfolio value over 90 days. Nu Med Plus is currently does not generate positive expected returns and assumes 8.6872% risk (volatility on return distribution) over the 90 days horizon. In different words, 78% of otc stocks are less volatile than NUMD, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Nu Med Target Price Odds to finish over Current Price
The tendency of NUMD OTC Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.01 | 90 days | 0.01 | about 98.0 |
Based on a normal probability distribution, the odds of Nu Med to move above the current price in 90 days from now is about 98.0 (This Nu Med Plus probability density function shows the probability of NUMD OTC Stock to fall within a particular range of prices over 90 days) .
Nu Med Price Density |
| Price |
Predictive Modules for Nu Med
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Nu Med Plus. Regardless of method or technology, however, to accurately forecast the otc stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the otc stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Nu Med Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Nu Med is not an exception. The market had few large corrections towards the Nu Med's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Nu Med Plus, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Nu Med within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.81 | |
β | Beta against Dow Jones | 0.37 | |
σ | Overall volatility | 0 | |
Ir | Information ratio | -0.1 |
Nu Med Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Nu Med for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Nu Med Plus can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Nu Med Plus generated a negative expected return over the last 90 days | |
| Nu Med Plus has high historical volatility and very poor performance | |
| Nu Med Plus has some characteristics of a very speculative penny stock | |
| Nu Med Plus currently holds 2.06 K in liabilities with Debt to Equity (D/E) ratio of 0.04, which may suggest the company is not taking enough advantage from borrowing. Nu Med Plus has a current ratio of 0.03, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Nu Med until it has trouble settling it off, either with new capital or with free cash flow. So, Nu Med's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Nu Med Plus sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for NUMD to invest in growth at high rates of return. When we think about Nu Med's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (830.06 K) with profit before overhead, payroll, taxes, and interest of 0. | |
| Nu Med Plus currently holds about 2.54 K in cash with (206.83 K) of positive cash flow from operations. | |
| Roughly 62.0% of Nu Med outstanding shares are owned by corporate insiders |
Nu Med Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of NUMD OTC Stock often depends not only on the future outlook of the current and potential Nu Med's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Nu Med's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 79.3 M | |
| Shares Float | 27.7 M |
Nu Med Fundamentals Growth
NUMD OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Nu Med, and Nu Med fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on NUMD OTC Stock performance.
| Return On Equity | -545.23 | |||
| Return On Asset | -6.62 | |||
| Current Valuation | 1.63 M | |||
| Shares Outstanding | 81.35 M | |||
| Price To Earning | 19.00 X | |||
| Price To Book | 49.86 X | |||
| EBITDA | (808.68 K) | |||
| Cash And Equivalents | 2.54 K | |||
| Total Debt | 2.06 K | |||
| Debt To Equity | 0.04 % | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (206.83 K) | |||
| Earnings Per Share | (0.01) X | |||
| Total Asset | 22.16 K | |||
| Retained Earnings | (2.41 M) | |||
| Current Asset | 57.17 K | |||
| Current Liabilities | 490.62 K | |||
About Nu Med Performance
By analyzing Nu Med's fundamental ratios, stakeholders can gain valuable insights into Nu Med's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Nu Med has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Nu Med has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Nu-Med Plus, Inc., a medical device company, engages in the design, development, enhancement, and commercialization of medical devices worldwide. Nu-Med Plus, Inc. was incorporated in 2011 and is headquartered in Salt Lake City, Utah. Nu Med operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 2 people.Things to note about Nu Med Plus performance evaluation
Checking the ongoing alerts about Nu Med for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Nu Med Plus help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Nu Med Plus generated a negative expected return over the last 90 days | |
| Nu Med Plus has high historical volatility and very poor performance | |
| Nu Med Plus has some characteristics of a very speculative penny stock | |
| Nu Med Plus currently holds 2.06 K in liabilities with Debt to Equity (D/E) ratio of 0.04, which may suggest the company is not taking enough advantage from borrowing. Nu Med Plus has a current ratio of 0.03, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Nu Med until it has trouble settling it off, either with new capital or with free cash flow. So, Nu Med's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Nu Med Plus sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for NUMD to invest in growth at high rates of return. When we think about Nu Med's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (830.06 K) with profit before overhead, payroll, taxes, and interest of 0. | |
| Nu Med Plus currently holds about 2.54 K in cash with (206.83 K) of positive cash flow from operations. | |
| Roughly 62.0% of Nu Med outstanding shares are owned by corporate insiders |
- Analyzing Nu Med's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Nu Med's stock is overvalued or undervalued compared to its peers.
- Examining Nu Med's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Nu Med's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Nu Med's management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Nu Med's otc stock. These opinions can provide insight into Nu Med's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for NUMD OTC Stock analysis
When running Nu Med's price analysis, check to measure Nu Med's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nu Med is operating at the current time. Most of Nu Med's value examination focuses on studying past and present price action to predict the probability of Nu Med's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nu Med's price. Additionally, you may evaluate how the addition of Nu Med to your portfolios can decrease your overall portfolio volatility.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |